Empiric dosing strategies to predict lamotrigine concentrations during pregnancy
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023
DOI: 10.1002/phar.2856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Verfasst von Jessica M Barry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Epilepsy, Pregnancy Complications. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, Epilepsy Foundation, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Introduction
Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy.
Objective
Our objective was to characterize the potential for particular dosing scenarios to lead to increased seizure risk or toxicity.
Methods
Lamotrigine pharmacokinetic parameters obtained from our previous study were applied to a one‐compartment model structure with subpopulations (75:25%) exhibiting different clearance changes. A single‐patient simulation was conducted with typical pharmacokinetic parameter values from each subpopulation. Population‐level simulations ( N = 48,000) included six dosing scenarios and considered four preconception doses using the R package mrgsolve (Metrum Research Group). Thresholds for efficacy and toxicity were selected as drug concentration that are 65% lower than preconception concentrations and doubling of preconception concentrations, respectively.
Results
Individual simulation results demonstrated that without dose increases, concentrations fell below 0.65 at 6–8 weeks in the high clearance change (HC) subpopulation, depending on preconception clearance. While no simulated dosing regimen allowed all women in both subpopulations to maintain preconception concentrations, some regimens provided a more balanced risk profile than others. Predicted concentrations suggested potential increased seizure risk for 7%–100% of women in the HC group depending on preconception dose and subpopulation. Additionally, in 63% of dosing scenarios for women with low clearance change (LC), there was an increased risk of toxicity (34%–100% of women). Significance A substantial percentage of simulated individuals had concentrations low enough to potentially increase seizure risk or high enough to create toxicity. Early clearance changes indicate possible subpopulation categorization if therapeutic drug monitoring is conducted in the first trimester. An arbitrary “one‐size‐fits‐all” philosophy may not work well for lamotrigine dosing adjustments during pregnancy and reinforces the need for therapeutic drug monitoring until a patient is determined to be in the LC or HC group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Neurology, New York University Comprehensive Epilepsy Center, New York City, New York, USA.
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Xenon Pharmaceuticals, Inc., Burnaby, British Columbia, Canada.
ORCID-Profile: Jessica M Barry, Jacqueline A French, Page B Pennell, Angela K Birnbaum
Förderung
- NICHD NIH HHS
- Epilepsy Foundation
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- University of Minnesota
Zitieren
APA
Barry, J. M., French, J. A., Pennell, P. B., Karanam, A., Harden, C. L., & Birnbaum, A. K. (2023). Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2856
Vancouver
Barry JM, French JA, Pennell PB, Karanam A, Harden CL, Birnbaum AK. Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2856
BibTeX
@article{Barry2023,
author = {Barry, Jessica M and French, Jacqueline A and Pennell, Page B and Karanam, Ashwin and Harden, Cynthia L and Birnbaum, Angela K},
title = {Empiric dosing strategies to predict lamotrigine concentrations during pregnancy},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
doi = {10.1002/phar.2856}
}
EUVIMED